Actively Recruiting
Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study
Led by University of Melbourne · Updated on 2026-05-06
530
Participants Needed
6
Research Sites
278 weeks
Total Duration
On this page
Sponsors
U
University of Melbourne
Lead Sponsor
T
The Alfred
Collaborating Sponsor
AI-Summary
What this Trial Is About
Thunderstorm asthma is a recurring public health emergency in South-Eastern Australia which occurs in springtime. The major identified risk factors for thunderstorm asthma is hay fever and allergy to ryegrass pollen. The goal of the CARISTA study is to identify the risk of springtime allergic and thunderstorm asthma in allergic adults living in South-Eastern Australia. To do this the investigators will recruit 530 people who have hay fever and test them for allergy to ryegrass pollen and undertake simple lung function testing. The investigators will ask study participants to complete a customised symptom tracker over the springtime pollen season for 2 consecutive years. The outcome the investigators are looking for is an asthma exacerbation or worsening asthma symptoms. This study will enable the investigators to identify indicators (biomarkers) of severe and moderate asthma exacerbations in order to identify those at risk of thunderstorm and seasonal asthma so protective treatments and strategies can be advised.
CONDITIONS
Official Title
Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Consenting adults aged 18 to 70 years with seasonal allergic rhinitis
- Willing to undertake lung function testing
- Willing to provide blood samples for risk factor identification
- Willing to prospectively log symptoms and medications during the spring season using the CARISTA symptom monitoring platform
You will not qualify if you...
- Unable to provide informed consent
- Do not have symptoms of seasonal allergic rhinitis
- Do not consent to lung function testing and blood sample collection
- Have unstable asthma (FEV1 less than 70% predicted), recent exacerbation, or change of asthma preventive medication within one month (re-screening allowed after one month)
- Have severe asthma requiring continuous oral corticosteroids or biological medication
- Have any medical illness or treatment that would compromise safety or biomarker derivation according to investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Albury-Wodonga Health
Albury, New South Wales, Australia, 2640
Actively Recruiting
2
Eastern Health
Box Hill, Victoria, Australia, 3128
Actively Recruiting
3
Monash Health
Clayton, Victoria, Australia, 3162
Actively Recruiting
4
Austin Health
Heidelberg, Victoria, Australia, 3084
Actively Recruiting
5
The Alfred Hospital
Melbourne, Victoria, Australia, 3004
Actively Recruiting
6
The Royal Melbourne Hospital
Parkville, Victoria, Australia, 3050
Actively Recruiting
Research Team
J
Jo A Douglass, MD
CONTACT
R
Rachel Tham, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here